Reviewing the thoroughness of human safety testing for succinate dehydrogenase inhibitors: fluopyram as a case study - Poll - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Evaluating the Completeness of Human Safety Assessments for Succinate Dehydrogenase Inhibitors: A Case Study of Fluopyram

  • By

  • Kim Z. Travis

  • Rémi Bars

  • Helen Tinwell

  • February 13, 2026

Share

Original Source(s)

Reviewing the thoroughness of human safety testing for succinate dehydrogenase inhibitors: fluopyram as a case study

  • by Kim Z. Travis, Rémi Bars, Helen Tinwell

  • February 13, 2026

Related Content

Expert evaluation of ChatGPT-generated responses to patient questions in conventional and fast-track total knee arthroplasty

2026 ASCO Breast Cancer Highlights: HER2CLIMB-05

Harold Burstein, MD, PhD, and Adrienne Waks, MD discuss the HER2Climb-05 trial and how it impacts treatment for HER2+ metastatic breast cancer

  • October 15, 2026

  • 1 min
Multimodal artificial intelligence in diabetes care: A scoping review